Anti-NMDAR encephalitis results from an antibody-mediated immune response against the NR1 subunit of the NMDA receptor. Psychiatric and behavioral symptoms are prominent, as are seizures (usually generalized tonic-clonic), dyskinesias, language dysfunction (more frequent in children), and autonomic instability (less frequent in children). Patients with the fulminant form often require prolonged hospitalization with cardiorespiratory support. Conversely, variations in presentation and the protracted course of symptom development can lead to delays in treatment and misdiagnosis. Originally described in 2007 as a paraneoplastic syndrome (especially in young women with ovarian teratomas), current evidence suggests it should be classifi ed as a neuroautoimmune syndrome, in which antibodies are formed in response to both tumors and infection. 1 The condition predominately affects women and younger individuals, with children comprising ∼40% of cases in 2 large series. 2, 3 In the April issue of Clinical Infectious Diseases, Gable et al 4 report on the frequency of anti-NMDAR encephalitis versus infectious etiologies on the basis of data from the California Encephalitis Project (CEP), a program established in 1998 to study the epidemiology and identify the etiologies of encephalitis. Physicians of patients with suspected encephalitis submit specimens to the CEP for diagnostic testing. The CEP case defi nition is: immunocompetent, ≥6 months of age, and under hospitalization for encephalopathy (altered mental status) with at least 1 clinical or diagnostic fi nding of fever, seizure, focal neurologic fi nding, CSF pleocytosis, EEG alteration, or neuroimaging abnormality. A standardized case history is submitted by the referring physician. Serum, CSF, and respiratory specimens are also submitted and tested for 15 potential agents, including herpesviruses, arboviruses, respiratory viruses, and Mycoplasma pneumoniae. Since 2007, if signs and symptoms are suggestive of anti-NMDAR encephalitis (eg, movement disorders, autonomic instability, psychosis), CEP contacts the referring physician to obtain consent for additional testing. Although serum testing for anti-NMDAR antibodies can be done, CSF testing is much more sensitive.
The authors studied cases of patients who presented to the CEP between September 2007 and February 2011 if they met the CEP case defi nition and were ≤30 years of age. 4 By using appropriate statistical techniques, the authors compared demographic characteristics, frequency, and clinical data of patients who tested positive for anti-NMDAR antibodies versus those with identifi ed infectious etiologies: enteroviruses, herpes simplex virus 1 (HSV-1), varicella-zoster virus (VZV), and West Nile virus (WNV).
In the 761 cases studied, an infectious etiology was identifi ed in 47 patients (enterovirus in 30 patients, HSV-1 in 7, and VZV and WNV in 5 each). 4 Another 47 patients were suspected of having anti-NMDAR encephalitis and were tested; 32 tested positive. Among the 79 encephalitis cases with a known etiology, anti-NMDAR encephalitis was signifi cantly more common than HSV-1 (41% vs 9%; P < .01), VZV (41% vs 6%; P < .01), and WNV (41% vs 6%; P < .01). Most (65%) anti-NMDA encephalitis cases occurred in patients aged ≤18 years. Females were affected signifi cantly more often than males, at ∼3 times the rate (P < .01), whereas other causes had no gender predilection. The article goes on to delineate differences in physical signs and symptoms, as well as laboratory, EEG, and imaging fi ndings between anti-NMDAR encephalitis and the infectious encephalitides. Financial data presented suggest that early testing in appropriate patients may be costeffective as well as life-saving.
Clearly the major limitation of this study 4 is referral bias. Referrals are voluntary and most likely refl ect more severe cases in which an etiology has not been determined after testing performed at other laboratories. Enteroviral and HSV PCRs are widely available, and (especially if positive) physicians may not pursue further testing or be unaware of the CEP. Despite this limitation, the authors add to the growing literature about the importance of this newly described condition, which has crucial diagnostic and treatment implications. Although there are other autoimmune mediators of encephalitis that are known and for which testing is possible, anti-NMDAR encephalitis seems to be the 1 more commonly reported in pediatric patients.
Treatments include potent immunosuppressant agents such as high-dose in travenous corticosteroids, intra venous immunoglobulin, anti-infl ammatory agents, plasmapheresis, and monoclonal antibodies. Patients often require intensive care and may be hospitalized for 2 to 14 months. Recovery, which may be incomplete, can take ≥3 years and relapse may occur in 20% to 25% of patients.
